Biomia
Biomia is a preclinical-stage synthetic biology company focused on developing novel small molecule therapeutics inspired by nature to treat central nervous system (CNS) disorders such as pain, mental health disorders, and addiction. The company uses a proprietary platform combining AI-driven drug discovery with yeast-based biomanufacturing to engineer and scale enantiopure, bioactive molecules with superior therapeutic potential. Biomia's pipeline includes drug candidates for chronic and neuropathic pain, schizophrenia, bipolar disorder, and opioid use disorder, positioning it as a leader in nature-inspired CNS drug discovery. The company has secured $3 million in pre-seed financing and has published significant research including the biosynthesis of the anti-cancer drug vinblastine. Biomia's business model is based on developing and advancing a pipeline of novel drug candidates through preclinical stages towards clinical trials, leveraging partnerships and its proprietary technology platform.
Biomia
Biomia is a preclinical-stage synthetic biology company focused on developing novel small molecule therapeutics inspired by nature to treat central nervous system (CNS) disorders such as pain, mental health disorders, and addiction. The company uses a proprietary platform combining AI-driven drug discovery with yeast-based biomanufacturing to engineer and scale enantiopure, bioactive molecules with superior therapeutic potential. Biomia's pipeline includes drug candidates for chronic and neuropathic pain, schizophrenia, bipolar disorder, and opioid use disorder, positioning it as a leader in nature-inspired CNS drug discovery. The company has secured $3 million in pre-seed financing and has published significant research including the biosynthesis of the anti-cancer drug vinblastine. Biomia's business model is based on developing and advancing a pipeline of novel drug candidates through preclinical stages towards clinical trials, leveraging partnerships and its proprietary technology platform.